Scientists have discovered that mRNA cancer vaccines activate the immune system in a more flexible way than previously thought, opening doors to more effective treatments for melanoma, lung cancer, and other tumors. Researchers at Washington University's Siteman Cancer Center found that even without one key immune cell type, mRNA vaccines still trigger powerful cancer-fighting responses by recruiting a backup immune cell to do the job .

What Makes mRNA Cancer Vaccines Different From COVID Vaccines?

When mRNA vaccines proved their worth during the COVID-19 pandemic, scientists quickly realized the same technology could fight cancer. Instead of teaching your immune system to recognize a virus, cancer vaccines deliver instructions for your cells to produce fragments of tumor proteins. Your immune system then learns to recognize and destroy cancer cells displaying those same proteins .

The key difference is personalization. While COVID vaccines target one virus, cancer vaccines can be customized to target the unique mutations in a patient's own tumor. This is why mRNA vaccines are currently in clinical trials for melanoma, small cell lung cancer, and bladder cancer, among others .

Which Immune Cells Actually Drive the Cancer-Fighting Response?

For years, scientists believed that a specific immune cell called cDC1 (classical type 1 dendritic cell) was essential for mRNA vaccines to work. These cells act like teachers, training T cells (the immune system's assassins) to recognize and destroy cancer cells. But the Washington University team discovered something unexpected: the immune system has a backup plan .

Researchers used mouse models lacking either cDC1 or a related cell type called cDC2 to test which cells were truly necessary. The results surprised them. Even without cDC1 cells, mice immunized with an mRNA vaccine generated strong T-cell responses and successfully cleared sarcoma tumors, which develop in connective tissues like muscle, fat, and bone .

The study, published in Nature on April 15, 2026, revealed that cDC2 cells can also activate T cells, but through a different mechanism. Instead of directly processing the mRNA instructions, cDC2 cells outsource the work to other cells. Those cells produce the tumor protein, break it into fragments, and then transfer the protein-fragment complex to the cDC2 cell through a process called "cross dressing." The cDC2 cell then presents these fragments to T cells, triggering the immune attack .

How to Optimize Cancer Vaccines Based on These Findings

• Vaccine Design: Understanding that both cDC1 and cDC2 cells contribute to the immune response allows researchers to design vaccines that work through multiple pathways, making them more robust and less dependent on a single cell type.
• Dosing Strategies: The discovery of different immune cell pathways could help scientists determine optimal vaccine doses and schedules, potentially improving how well patients respond to treatment.
• Patient Response Prediction: Identifying the molecular "fingerprints" that T cells show when activated by different dendritic cells may help doctors predict which patients will respond best to mRNA cancer vaccines.

"This work uncovers a new way mRNA vaccines engage the immune system, through both cDC1 and cDC2, which helps explain their power and gives researchers concrete targets for making future mRNA cancer vaccines more effective," stated William E. Gillanders, MD.

William E. Gillanders, MD, Mary Culver Professor of Surgery at Washington University Medicine

Gillanders, who also developed an investigational vaccine against triple-negative breast cancer, emphasized that these insights could improve vaccine formulation and dosing, potentially explain why some patients respond better to vaccines than others, and guide strategies for making vaccines more effective .

Why Does This Matter for Melanoma and Lung Cancer Patients?

The flexibility of the mRNA vaccine system is a game-changer. Because the immune system can activate T cells through multiple pathways, vaccines are less likely to fail if a patient's immune system is missing or has reduced numbers of one particular cell type. This redundancy makes mRNA vaccines potentially more reliable across diverse patient populations .

For melanoma specifically, this research is particularly significant. Melanoma incidence has risen markedly over the past three decades, and immunotherapy approaches like mRNA vaccines offer new hope for patients with advanced disease. The same applies to small cell lung cancer, one of the most aggressive forms of lung cancer .

"By dissecting which immune cells are involved and how they coordinate the response, we're offering vaccine developers some additional mechanistic insights to consider in their goal of optimizing these vaccines against tumor proteins," explained Kenneth M. Murphy, MD, PhD.

Kenneth M. Murphy, MD, PhD, Eugene Opie Centennial Professor of Pathology and Immunology at Washington University Medicine

The research also revealed that T cells activated by cDC1 and cDC2 show slightly different molecular signatures. These differences could help scientists design better vaccine versions in the future, tailoring treatments to individual patient needs .

As mRNA cancer vaccines move through clinical trials, this deeper understanding of how they work will be crucial. The more researchers understand the immune mechanisms at play, the better they can refine these treatments to maximize effectiveness and minimize side effects. For patients facing melanoma, lung cancer, and other malignancies, that means hope for more powerful, personalized treatment options in the years ahead.